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        Cancer usually occurs sporadically, is clonal in 
origin, and is the result of a stepwise accumula-
tion of mutations that progressively lead to 
malignancy. Between the initiating oncogenic 
event and tumor progression, there is a variable 
and sometimes very long premalignant phase 
that is clinically unapparent. Most if not all tu-
mors evoke immune reactivity at some point, 
but when is not clear. Analysis of the tumor-
induced CTL response has shown contradic-
tory results in that tumors alternatively induced 
functional CTLs, anergized or deleted CTLs, 
induced functional CTLs followed by their 
inactivation, or were ignored by CTLs (  1  –  8  ). 
These data were obtained by exposing the host 
to a large number of tumor cells at a single time 
point (e.g., by tumor transplantation experi-
ments or in mice expressing a tumor antigen/
oncogene in an organ-specifi  c fashion), which 
leaves the question of the relevance for sporadic 
tumors open. Because in the current sporadic 
tumor models no defi  ned tumor antigen is 
known, the adaptive immune response to spo-
radic premalignant lesions (PMLs) has not been 
previously analyzed. 
  Defective CTL responses against antigens 
not expressed by the tumor have been shown 
in several tumor models. This tumor-induced 
immune suppression has been attributed to tu-
mor burden (  9  –  11  ). Tumor burden also in-
duces the expansion of CD11b/Gr-1  +   cells, 
termed immature myeloid cells (iMCs) (  12, 13  ). 
iMCs have been shown to inhibit CTL responses 
to unrelated antigens in vitro and support tu-
mor growth in vivo, e.g., by promoting tumor 
angiogenesis (  14  –  21  ). iMCs are thought to 
directly inhibit CTL responses by their increased 
frequency and production of immune-sup-
pressive molecules, but more complex mecha-
nisms have also been proposed (  22  –  25  ). Again, 
the role these fi  ndings have for sporadic cancer 
is unknown. 
  We have previously described a transgenic 
mouse model of sporadic cancer. The mice, 
termed LoxP-Tag, harbor the SV40 T-antigen 
(Tag), which is silent because of a stop cassette 
separating a ubiquitously active promoter and 
the oncogene (  26  ). By rare stochastic events, 
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the oncogene is activated in single cells that express Tag as a 
dominant tumor-specifi   c transplantation rejection antigen. 
Prophylactic immunization prevented tumors throughout life, 
indicating that the mice, in principle, can eff  ectively respond 
to Tag and generate protective T cells. Tumors that appeared 
after a usually long latency in naive mice did not escape T cell 
recognition in their primary host and were highly immuno-
genic; e.g., they were rejected after injection into naive T 
cell  –  competent mice. In their primary host, the progressively 
growing tumors elicited a strong Tag-specifi  c IgG antibody 
response and the expansion of Tag-specifi  c CD8  +   T cells 
with an anergic phenotype (  26  ). These data argued against 
the assumption that spontaneous tumors escape T cell de-
struction by losing immunogenicity. However, the time point, 
mechanism, and specifi  city of tolerance induction and the 
potential role of tumor immunogenicity versus tumor burden 
for impaired T cell function remained unclear. 
    RESULTS   
  Sporadic immunogenic tumors induce general 
CTL unresponsiveness 
  To begin, we analyzed whether tolerance induced by spo-
radic immunogenic tumors is specifi  c for Tag, the transplan-
tation rejection antigen expressed by tumors in LoxP-Tag 
transgenic mice, or is accompanied by CTL hypo- or unre-
sponsiveness against unrelated antigens. Therefore, we ana-
lyzed by an in vivo kill assay the ability of female tumor-bearing 
mice to mount a primary CTL response against male-specifi  c 
minor histocompatibility antigens, collectively termed HY. 
Mice were immunized with male spleen cells or left un-
treated, and were injected 2 wk later with equal numbers of 
male and female spleen cells labeled with diff  erent amounts of 
CFSE. After 18  –  24 h, the disappearance of CFSE-labeled 
cells was analyzed. Although no disappearance of the male 
spleen cells was observed in nonimmunized female mice and 
immunized male mice, in immunized old C57BL/6 (B6) and 
young tumor-free LoxP-Tag mice (Tg), both females, the 
CFSE-labeled male spleen cells were signifi  cantly decreased 
in comparison to female cells (  Fig. 1 A  ; and   Fig. 1 B  , all sum-
marized data).   In contrast, immunized female LoxP-Tag mice 
with large tumors did not kill the CFSE-labeled male spleen 
cells above background. To confi  rm the data, the CTL re-
sponse against the LCMV-gp33 peptide was analyzed. B6 
and tumor-bearing LoxP-Tag mice were immunized with 
    Figure 1.         Sporadic immunogenic tumors induce CTL unresponsive-
ness to unrelated antigens.   CTL activity against the minor histocompat-
ibility antigens (HY) and the LCMV peptide epitope gp33 was analyzed in 
vivo. (A and B) For analysis of HY-specifi  c CTLs, female and male spleen 
cells (10  7   each) labeled with different amounts of CFSE were injected into 
the indicated mice, and 18 h later the ratio between both populations in 
the spleen was determined by fl  ow cytometry. Immunization was per-
formed by a single i.p. injection of 5   ×   10  6   male C57BL/6 spleen cells 2 wk 
before the assay. The percentage of specifi  c killing of male cells is indi-
cated. One representative example per experimental group is shown in A, 
and all data are shown in B (horizontal bars indicate mean values). Serum 
anti-Tag antibody titers (mg/ml) are given for tumor-bearing mice. Geno-
type (B6, C57BL/6; Tg, LoxP-Tag), age, cancer status (     , no tumor; LTB), 
treatment (N/     , naive; I/+, immunized), and gender of mice (f, female; 
m, male) are indicated. Experimental groups were young naive female 
C57BL/6 mice (B6; 2  –  3 mo old;   n   = 5), young immunized male C57BL/6 
mice (B6; 2  –  3 mo old;   n   = 3), young immunized female LoxP-Tag mice 
(Tg; 2  –  3 mo old;   n   = 7), old immunized female C57BL/6 mice (B6; 15 mo 
old;   n   = 4), and LTB female LoxP-Tag mice (Tg; 7  –  19 mo old;   n   = 6). n.a., 
not analyzed. (C and D) For analysis of LCMV-gp33 peptide  –  specifi  c CTLs, 
nonloaded and LCMV-gp33 peptide  –  loaded spleen cells (10  7   each)  labeled 
with different amounts of CFSE were injected into the indicated mice, and 
18 h later the ratio between both populations was determined by fl  ow 
cytometry. Mice were immunized by a single s.c. injection of 10  7   cells  of 
tumor line MC57-gp33-Hi 8  –  10 d before the assay. The percentage of 
specifi  c killing of peptide loaded cells is indicated. Representative ex-
amples are shown in C, and all data are shown in D (horizontal bars indi-
cate mean values). Genotype (B6, C57BL/6; Tg, LoxP-Tag), age, cancer 
status (     , no tumor; LTB), and treatment (N/     , naive; I/+, immunized) are 
indicated. Experimental groups were young naive C57BL/6 mice (B6; 2  –  3 
mo old;   n   = 5), young immunized C57BL/6 mice (B6; 2  –  3 mo old;   n   = 6), 
and LTB LoxP-Tag mice (Tg; 19 mo old;   n   =  4).   
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MC57 cells that express large amounts of the gp33 peptide 
(  27  ), and an in vivo kill assay with gp33 peptide  –  loaded 
spleen cells was performed 8  –  10 d later. Although a substantial 
kill of peptide-loaded spleen cells was observed in B6 mice, 
no signifi  cant kill was observed in tumor-bearing LoxP-Tag 
mice (  Fig. 1 C  ; and   Fig. 1 D  , all summarized data). These 
data show that sporadic immunogenic tumors induce general 
CTL unresponsiveness. 
  Tag-specifi  c tolerance in mice with PMLs 
  We asked when Tag-specifi  c tolerance occurred relative to 
the time point of the fi  rst measurable tumor antigen recogni-
tion by the adaptive immune system. This way, we also indi-
rectly addressed the question of whether LoxP-Tag mice 
developed concomitant immunity (  28  ) at an early stage of tu-
mor growth. Thus far, the best surrogate marker for tumor 
development in LoxP-Tag mice are Tag-specifi  c IgG anti-
bodies (  26  ). Approximately 90% of the mice had developed 
anti-Tag IgG antibodies at the time of obvious tumor burden. 
Usually, these antibodies occurred many months before tumor 
burden, indicating a long latency between the initiating onco-
genic event and tumor progression. By measuring anti-Tag 
IgG antibodies in the serum of LoxP-Tag mice, we identifi  ed 
a group of mice between 6  –  14 mo of age that had recently 
developed low anti-Tag IgG antibody titers (  Fig. 2 A  ).   Be-
cause macroscopically visible tumors could rarely be detected 
in such mice, they were termed PML mice. As a control, 15  –
  19-mo-old mice were used that had high anti-Tag IgG anti-
body titers and macroscopically detectable tumors, termed 
large tumor  –  bearing (LTB) mice. Because in most cases tu-
mors grew in internal organs, a fact that makes the judgment 
of tumor status diffi   cult, the mice were routinely analyzed at 
the end of the experiment for PML or LTB status. The mice 
were subjected to an in vivo kill assay with spleen cells loaded 
with peptide IV, the dominant epitope of Tag (  29, 30  ). As a 
further control, young (tumor-free) LoxP-Tag mice were im-
munized by a challenge with 16.113 cells, a Tag-positive re-
gressor tumor derived from LoxP-Tag mice (  26  ). Immunized 
but not naive young LoxP-Tag mice showed a substantial kill 
of Tag peptide IV  –  loaded spleen cells (  Fig. 2 B  ). Immunized 
old (6  –  19 mo) B6 mice also effi   ciently lysed Tag peptide IV  –
  loaded target cells. The PML mice with low anti-Tag IgG an-
tibodies (  Fig. 2 A  ) were unable to kill Tag peptide  –  loaded 
spleen cells above background (  Fig. 2 B  ). Assuming that the 
time of recognition of the tumor antigen by CTLs and induc-
tion of anti-Tag IgG antibodies do not substantially differ 
from each other, the data suggest that Tag-specifi  c CTL toler-
ance occurred almost simultaneously with the fi  rst detection 
of anti-Tag IgG antibodies. This also indicates that we failed 
to detect a phase of concomitant immunity, during which ini-
tially functional CTLs were generated. Even after immuniza-
tion with 16.113 cells, LTB LoxP-Tag mice were unable to 
kill Tag peptide IV  –  loaded spleen cells (  Fig. 2 B  ). This was 
not caused by the advanced age of the mice, because immu-
nized old (6  –  19 mo) B6 mice showed lytic activity compara-
ble to that of young (2  –  3 mo) LoxP-Tag mice (  Fig. 2 B  ). 
    Figure 2.         Tag-specifi  c CTL cell tolerance occurs almost simul-
taneously with the development of Tag-specifi  c antibodies.   (A)  To 
identify LoxP-Tag mice that had most recently immunologically rec-
ognized PMLs (open symbols;   n   = 6), anti-Tag IgG antibodies were 
measured as indicated in individual mice. As a control, mice that al-
ready had detectable anti-Tag antibodies for several months (LTB 
mice; closed symbols;   n   = 4) were used. (B) CTL activity against the 
Tag-specific peptide IV was analyzed in vivo in PML mice (6  –  14 mo 
old) and LTB mice (16  –  19 mo old) shown in A. Therefore, nonloaded 
and peptide IV  –  loaded splenocytes labeled with different amounts of 
CFSE were injected into the respective mice and as a control into 
young naive (2  –  3 mo old;   n   = 2) and immunized LoxP-Tag transgenic 
mice (2  –  3 mo old;   n   = 3), and aged C57BL/6 mice (B6; 6  –  19 mo old; 
  n   = 5). 18 h later the ratio between both populations was determined 
by flow cytometry of spleen cells. The percentage of specific killing of 
peptide-loaded cells is indicated (horizontal bars indicate mean val-
ues). Genotype (B6, C57BL/6; Tg, LoxP-Tag), age, cancer status (    ,  no 
tumor; PML; LTB), and treatment (     , naive; +, immunized) are indi-
cated. (C) LoxP-Tag mice at      6  –  9 mo of age have developed Tag-
specific tolerance. 10  6   cells of Tag-expressing tumor line 16.113 were 
s.c. injected into 3-mo-old Rag-2       /       mice (  n   = 4), as well as 3-mo-old 
(  n   = 4), 6-mo-old (  n   = 4), 9-mo-old (  n   = 4), and 13-mo-old (  n   =  3) 
LoxP-Tag mice, and tumor growth was observed. Error bars represent 
SD. The age and number of mice with tumor per number of mice in 
the experiment are shown in parenthesis.     1690 IMMUNOGENIC CANCER CAUSES GENERAL CTL UNRESPONSIVENESS   | Willimsky et al. 
  To confi  rm these data, LoxP-Tag mice of diff  erent ages 
(6, 9, and 13 mo) were injected with 16.113 cells that are 
regularly rejected in 3-mo-old LoxP-Tag mice (  Fig. 2 C  ). 
In all mice of 9 and 13 mo of age (4 out of 4 and 3 out of 3, 
respectively) and in 2 out of 4 mice injected at the age of 
6 mo, the transplanted tumor was not rejected. In the 6-mo-
old mice, it was those with anti-Tag IgG antibodies that did 
not reject 16.113 cells (unpublished data). These data demon-
strate that in the majority of LoxP-Tag mice, Tag-specifi  c 
tolerance occurred around 6  –  9 mo of age, coinciding with 
the initial detection of anti-Tag IgG antibodies. Because 
in these PML mice usually no macroscopic tumors could be 
detected, and because of the long latency until obvious tu-
mor burden (due to the stochastic nature of the tumor model 
between 12 and   >  24 mo), we conclude that Tag-specifi  c 
tolerance occurred in mice with PMLs. This also indicates 
that the tumor latency is unlikely caused by Tag-specifi  c 
CTL-mediated mechanisms. 
  Persistent tumor antigen causes general CTL 
unresponsiveness subsequent to Tag-specifi  c tolerance 
  We next analyzed when general CTL unresponsiveness oc-
curred relative to Tag-specifi  c tolerance. LoxP-Tag mice of 
diff  erent ages (7, 10  –  12, and 17 mo) were analyzed for HY-
specifi  c CTLs and retrospectively anti-Tag IgG antibodies in 
the blood were determined. Immunized but not naive female 
B6 mice specifically killed the CFSE-labeled male spleen 
cells. Immunized 7-mo-old female LoxP-Tag mice had es-
sentially normal anti-HY CTL responses even though some 
of the mice already had anti-Tag IgG antibodies (  Fig. 3 A  ).   
At 10  –  12 mo of age, anti-HY CTL responses were decreased 
in several LoxP-Tag mice, mostly those with anti-Tag anti-
bodies in the serum. However, another portion of this group, 
    Figure 3.         Tag-specifi  c tolerance and general CTL unresponsiveness 
are induced consecutively.   (A)  HY-specifi  c CTL activity 2 wk after immu-
nization of female LoxP-Tag mice of different ages (7, 10  –  12, and 17 mo) 
with 5   ×   10  6   male spleen cells was determined by in vivo kill assay, as 
described in   Fig. 1  . Female and male spleen cells were injected into the 
indicated mice, and 18 h later the ratio between both populations in the 
spleen was determined by fl  ow cytometry. The percentage of specifi  c kill-
ing of male cells is indicated (horizontal bars indicate mean values), and 
numbers give the anti-Tag IgG antibody titers (mg/ml) in the serum of 
corresponding mice. Anti-Tag IgG antibody titers in the serum (mg/ml) are 
indicated if mice were positive. n.a., not analyzed. (B) 6  –  13-mo-old LoxP-
Tag mice were fi  rst immunized with 5   ×   10  6   male spleen cells and 1 wk 
later challenged s.c. with 10  6   Tag-expressing 16.113 cells. Mice in which 
challenge tumors were not rejected and that had a tumor size of 8  –  10 mm 
in diameter (open symbols;   n   = 8) were boosted with 5   ×   10  6   male  spleen 
cells and subjected to an HY-specifi  c in vivo kill assay 2 wk later. Identically 
treated 2-mo-old C57BL/6 mice (B6;   n   = 4) and LoxP-Tag mice (Tg;   n   =  2) 
were used as controls (closed symbols). The percentage of specifi  c killing 
of male cells is indicated (horizontal bars indicate mean values). Anti-Tag 
IgG antibody titers in the serum (mg/ml) are indicated if mice were posi-
tive. n.d., not detectable. (C) 6- and 12-mo-old LoxP-Tag mice reject re-
gressor tumor cells expressing gp33. 10  6   cells of gp33-expressing tumor 
line MC57-gp33-Hi were s.c. injected into 3-mo-old Rag-2       /       (  n   =  3), 
6-mo-old LoxP-Tag (  n   = 3), and 12-mo-old LoxP-Tag (  n   = 3) mice, and 
tumor growth was observed. The age and number of mice with tumor per 
number of mice in the experiment is shown in parenthesis. (D) LoxP-Tag 
mice shown in C that rejected MC57-gp33-Hi regressor tumor cells were 
immunized with Tag  +   16.113 cells, and 9 d later were analyzed for CTL 
activity against the Tag-specifi  c peptide IV in vivo. Therefore, nonloaded 
and peptide IV  –  loaded splenocytes labeled with different amounts of CFSE 
were injected into the respective mice and as a control into young naive 
and immunized C57BL/6 mice (2 mo old;   n   = 2, respectively). 18 h later, 
the ratio between both populations was determined by fl  ow cytometry of 
spleen cells. The percentage of specifi  c killing of peptide-loaded cells is 
indicated (horizontal bars indicate mean values).     
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not only those without anti-Tag antibodies, showed a normal 
HY-specifi  c kill. In 17-mo-old LoxP-Tag mice, no HY-spe-
cifi  c kill was detected. In another experiment, LoxP-Tag mice 
between 6  –  13 mo of age were challenged with 16.113 cells, 
and those mice that did not reject the transplanted tumor 
and, thus, had developed Tag-specifi  c tolerance were sub-
jected to an in vivo anti-HY kill assay. Several mice with 
16.113 tumors had decreased anti-HY CTL activity, but an-
other group of mice that was unable to reject 16.113 cells had 
normal anti-HY lytic CTL activity (  Fig. 3 B  ). These data in-
dicate that general CTL unresponsiveness occurred subse-
quent to Tag-specifi  c tolerance and was probably caused by 
the persistent strong tumor antigen. If this assumption was 
correct, LoxP-Tag mice that recently had developed Tag-
specifi  c tolerance might still be able to reject antigenically 
unrelated regressor tumor cells. To address this question, LoxP-
Tag mice at 6 or 12 mo of age were challenged with MC57-
gp33-Hi cells that are rejected in naive B6 mice and elicit 
gp33-specifi  c CTLs (  Fig. 1, C and D  ) (  27  ). As shown in   Fig. 
3 C  , tumors grew in Rag-2       /       mice but were rejected in 
LoxP-Tag mice. The latter mice were then immunized by 
injection of 16.113 cells and analyzed by in vivo kill assay for 
Tag peptide IV  –  specifi  c CTLs. Two out of three LoxP-Tag 
mice at 6 mo of age and three out of three mice at 12 mo of 
age did not show signifi  cant peptide IV  –  specifi  c CTL activity 
(  Fig. 3 D  ). Thus, shortly after having developed Tag-specifi  c 
CTL tolerance, LoxP-Tag mice appear to have normal CTL 
responses against unrelated targets. 
  Primary but not memory CTL responses are impaired 
in old LoxP-Tag mice 
  To distinguish whether anti-HY CTL responses were inhib-
ited in the priming/expansion or eff  ector phase, the frequency 
of D  b  /UTY-tetramer  –  binding CD8  +   T cells was analyzed in 
LoxP-Tag mice with diff  erent anti-HY CTL activity, de-
scribed in   Fig. 3 (A and B)  . UTY is an HY antigen for which 
the H2-D  b    –  presented peptide sequence is known (  31  ). In 
most immunized female B6 and 2-mo-old LoxP-Tag mice, 
     2  –  4% of the CD8  +   T cells were D  b  /UTY-tetramer positive, 
correlating with high cytolytic activity (  Fig. 4, A and B  ).   Non-
immunized mice contained   <  0.03% double-positive cells. In 
most of the older LoxP-Tag mice, especially the 6  –  7- and 10  –
  13-mo-old groups, the decrease of anti-HY CTL activity was 
proportional to the decrease of D  b  /UTY-tetramer  –  binding 
cells, suggesting that the priming/expansion of anti-HY CTLs 
was inhibited. However, regardless of tumor burden, in some 
17  –  19-mo-old mice a slight increase in the frequency of D  b  /
UTY-tetramer  –  positive CD8  +   T cells was detected, even 
though no anti-HY cytolytic activity was detected in these mice 
(  Fig. 4 B  ). We cannot exclude, therefore, that CTL eff  ector 
function was also inhibited. 
  The aforementioned experiments addressed the question 
of whether primary unrelated CTL responses were impaired 
in old LoxP-Tag mice. Next, we asked whether memory 
CTL responses were also inhibited in old LoxP-Tag mice. A 
group of female LoxP-Tag mice were immunized at the age 
    Figure 4.         Primary but not memory CTL responses are suppressed in 
old LoxP-Tag mice.   (A) HY-immunized mice shown in   Fig. 3 (A and B)   were 
analyzed for the presence of UTY-specifi  c T cells by staining spleen cells with 
anti-CD8 mAbs and H-2D  b  /UTY tetramers. One representative example of 
fl  ow cytometric analysis for each experimental group is shown. The per-
centage of UTY-specifi  c tetramer-positive CD8  +   T cells is indicated. (B) The 
percentage of HY-specifi  c killing is plotted against the percentage of 
UTY-specifi  c tetramer-positive CD8  +   T cells from experiments shown in   Fig. 3 
(A and B)  . (C) Memory CTL responses against unrelated antigens are not 
generally inhibited in aged LoxP-Tag mice. 2-mo-old female LoxP-Tag and 
C57BL/6 mice were immunized three times with 5   ×   10  6   male spleen cells 
(prime). At the age of 18  –  19 mo, these mice were reimmunized with 5   ×   10  6   
male spleen cells (boost), and HY-specifi  c CTL activity was determined 2 wk 
later by in vivo kill assay, as described in   Fig. 1  . CFSE-labeled female and male 
spleen cells were injected into the indicated mice, and as a control into 
2-mo-old naive C57BL/6 (B6;   n   = 2), immunized C57BL/6 mice (B6;   n   =  2), 
and immunized 18-mo-old LoxP-Tag mice (Tg;   n   = 2). 18 h later, the ratio 
between both populations was determined by fl  ow cytometry. The percent-
age of specifi  c killing of male cells is indicated (horizontal bars indicate mean 
values). Genotype (B6, C57BL/6; Tg, LoxP-Tag), age, cancer status (    ,  tumor-
free; PML), and treatment (     , naive; +/     , immunized once at the indicated 
age; +/+, primed at 2 mo/boosted at the indicated age) are indicated.    1692 IMMUNOGENIC CANCER CAUSES GENERAL CTL UNRESPONSIVENESS   | Willimsky et al. 
LoxP-Tag mice that had not been immunized at the age of 
2 mo failed to mount anti-HY CTL responses after primary 
immunization at the age of 18 mo (  Fig. 4 C  ). In contrast, 
old LoxP-Tag mice that had been immunized at 2 mo 
showed normal anti-HY cytolytic activity, comparable to 
age-matched nontransgenic control mice. Thus, the persis-
tent tumor antigen inhibits primary but not memory CTL 
responses against unrelated antigens. 
  Detection of premalignant immunogenic lesions 
in Tag-tolerant mice 
  In those mice designated as LTB mice, obvious tumor burden 
was detected by magnet resonance tomography (  Fig. 5 A  ) that 
was confi  rmed by immunohistology with an anti-Tag anti-
body (  Fig. 5 B  ).   However, in the majority of mice that were 
tolerant for Tag and/or had shown general CTL unrespon-
siveness, no macroscopically visible or magnetic resonance 
imaging (MRI)  –  detectable primary tumor could be detected. 
Detection of PMLs was diffi   cult; because of the stochastic na-
ture of the model, not only the tumor latency but also tumor 
location can be variable from mouse to mouse. Because LoxP-
Tag mice frequently develop renal cancer, the kidneys of sev-
eral mice were analyzed for PMLs. To not miss any small 
PMLs, the entire kidneys of seven mice were cross sectioned 
in 4-  μ  m steps; every 10th section was analyzed for pathological 
alterations and, if early lesions were detected, consecutive sec-
tions were stained with diff  erent antibodies. Comparable to 
the frequency of renal cell carcinoma in four out of seven 
mice, microscopically small cell clusters that stained positive 
with an anti-Tag antibody were detected in the kidneys (  Fig. 
5 C  ; and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20072016/DC1). These cell clusters that were 
not larger than 1 mm in diameter were defi  ned as premalig-
nant because they additionally stained positive for the prolifer-
ation marker Ki-67 (  Fig. 5 C   and Fig. S1). In the kidneys of 
the four mice, between two and fi  ve Tag-positive lesions were 
detected, for which we do not know whether they were clon-
ally related or independent lesions. According to the age of the 
analyzed mice (6  –  7 mo) and the mean time until obvious tu-
mor burden (between 12 and   >  24 mo), these premalignant le-
sions may have been unapparent for a long time. Remarkably, 
proportionally to the size of the PMLs a strong T cell infi  ltrate 
(CD3  +  ) was detected (  Fig. 5 C   and Fig. S1). Because these 
mice were shown either to fail to reject 16.113 tumor cells or 
to be unable to kill Tag peptide IV  –  loaded spleen cells and, 
therefore, were tolerant for Tag, the role of these T cells, 
whose phenotype and antigen specifi  city are unknown, re-
mains to be analyzed. However, the T cells infi  ltrating PMLs 
were negative for FoxP3, a marker for regulatory T cells (  Fig. 
5 C  , Fig. S1, and Fig. S2). Even though we cannot exclude 
that further Tag-positive lesions in other organs escaped our 
attention, the data demonstrate that the PMLs have the ap-
pearance of being highly immunogenic despite Tag-specifi  c 
CTL tolerance, because they contain a strong T cell infi  ltrate 
and the mice produce anti-Tag IgG antibodies. Furthermore, 
general CTL unresponsiveness appears to be initiated in mice 
of 2 mo with male spleen cells, as above. At 18 mo, when 
most LoxP-Tag mice were unable to respond to male spleen 
cell immunization in the previous experiments (  Fig. 1 B and 
Fig. 3 A  ), the mice were subjected to an in vivo anti-HY 
CTL kill assay 2 wk after booster immunization. As before, 
    Figure 5.         Detection of tumors and PMLs in LoxP-Tag mice.   (A)  Tumors 
in LTB mice were detected by MRI. Shown are representative transversal and 
coronal MR images of a kidney tumor (#1) and a tumor in the bone (#2); 
tumors are indicated by white circles. (B) Immunohistology of tissue sections 
in LTB mice. Tissues were stained for Tag, Ki-67, CD3 (red), FoxP3 (brown), 
and F4/80 (red) expression and counterstained with hematoxylin. Bar, 200   μ  m. 
(C) Representative PMLs in mice that recently developed anti-Tag anti-
bodies but without macroscopically detectable tumors. Kidneys of 6  –  7-mo-
old LoxP-Tag mice, which were shown to have developed tumor-induced 
tolerance, were cross sectioned in 4-  μ  m steps and examined for the presence 
of PMLs by staining with hematoxylin and eosin (not depicted). Consecutive 
sections of identifi  ed PMLs were stained with mAbs as in B. In four out of 
seven mice analyzed, PMLs were detected in the kidney. Lymph nodes ob-
tained from tumor-free mice served as a positive control for FoxP3 staining 
(Fig. S2, available at http://www.jem.org/cgi/content/full/jem.20072016/DC1). 
Staining of additional PMLs is shown in Fig. S1. Bar, 100   μ  m.    JEM VOL. 205, July 7, 2008 
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mice were crossed to Alb-Cre transgenic mice that express 
the Cre recombinase in a liver-specifi  c fashion. Because of 
the early deletion of the stop cassette and Tag expression in a 
Cre-LoxP  –  mediated fashion, the mice are tolerant for Tag. 
They do not produce anti-Tag antibodies, accept Tag-posi-
tive tumor grafts that are rejected in young tumor-free LoxP-
Tag mice (  26  ), and cannot kill Tag peptide IV  –  loaded spleen 
cells after immunization (  Fig. 7 A  ).   At approximately weeks 
12  –  16, they have developed large liver tumors, as analyzed 
by MRI (  Fig. 7 B  ) and immunohistology (  Fig. 7 C  ), that are 
non- (or low-) immunogenic, because Tag is the dominant 
transplantation rejection antigen (  26  ). Female LoxP-Tag   ×   
Alb-Cre double-transgenic mice were analyzed for HY-spe-
cific CTLs as above. Immunized mice with large tumors 
killed transferred CFSE-labeled male spleen cells almost as 
effi   ciently as normal B6 mice (  Fig. 7 D  ). These data demon-
strate that although small immunogenic PMLs induce general 
CTL unresponsiveness, large nonimmunogenic tumors do not. 
Surprisingly, LoxP-Tag   ×   Alb-Cre double-transgenic mice 
had by far the highest frequency of iMCs in the spleen (means 
of 45% CD11b/Gr-1  –   and 22% c-kit/Gr-1  –  positive;   Fig. 6, 
A and B  ), but they had normal serum TGF-     1 concentra-
tions (  Fig. 6 C  ). These data support the notion that tumor 
burden increases iMCs (  15, 32  ), but also show that large 
numbers of tumor-induced iMCs per se are not suffi   cient to 
inhibit CTL responses against unrelated antigens. Based on a 
few additional indicative markers (F4/80, IL-4 receptor, and 
Fc      receptor), no signifi  cant phenotypic diff  erence of CD11b-
positive cells from LoxP-Tag compared with LoxP-Tag   ×   
Alb-Cre mice was observed, with the exception that based 
on higher F4/80 expression, CD11b-positive cells from aged 
single-transgenic mice appeared to have a more mature phe-
notype (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20072016/DC1). The tumor-induced expansion of 
iMCs without an obvious need to inhibit CTL responses in-
dicates that their primary function is the direct support of tu-
mor growth, as previously suggested (  16  ). 
    DISCUSSION   
  When are cancer cells recognized by adaptive immune cells? 
What is the outcome of the initial recognition? And what are 
the consequences of long-term tumor antigen reactivity? 
Answers to these questions are the key to the question of 
whether T cells spontaneously control autochthonous tu-
mors, termed cancer immunosurveillance. Previous studies 
did not allow these questions to be addressed because of the 
lack of suitable models (  33  ). 
  Antigen-defi  ned sporadic cancer model 
  Most data on antitumor T cell responses have been obtained 
by exposing the host to an artifi  cially large number of tumor 
cells at a single time point, e.g., by tumor transplantation ex-
periments or in transgenic models with tissue-specifi  c onco-
gene/tumor antigen expression. In other models (e.g., chemical 
carcinogenesis), it is not possible to analyze specifi  c T cell 
responses because no tumor antigen is known. Additionally, 
with PMLs, with no indication of local FoxP3  +   T cell involve-
ment. PMLs were also infi  ltrated by F4/80-positive cells (  Fig. 
5 C   and Fig. S1), representing the major infl  ammatory com-
ponent of the developing stroma in these lesions. 
  General CTL unresponsiveness is associated 
with an increase of iMCs and TGF-    1 
  To search for a mechanism of the general CTL unresponsive-
ness we analyzed iMCs, a cell population known to nonspe-
cifi  cally inhibit CTL responses (  15, 18, 24  ). An analysis of 
spleens from LTB LoxP-Tag mice showed that iMCs, de-
tected by antibodies specifi  c for CD11b/Gr-1 or Gr-1/c-kit, 
were signifi  cantly expanded in comparison to young tumor-
free LoxP-Tag and old B6 mice (  Fig. 6 A  ; and   Fig. 6 B  , all 
summarized data).   Spleen cells from young LoxP-Tag and 
old B6 mice contained 5  –  7% CD11b/Gr-1  –  positive and 
0.5  –  3% c-kit/Gr-1  –  positive cells, with those from LTB mice 
containing means of 22 and 8%, respectively. iMCs were al-
ready slightly increased in mice with PMLs (mean of 10% 
CD11b/Gr-1  –  positive cells). Despite variability between mice 
of the same group, it appeared that iMC expansion correlated 
with progressive tumor growth (  Fig. 6 B  ). Substantial num-
bers of iMCs were also detected in tumors (  Fig. 6, A and B  ). 
LTB LoxP-Tag mice had substantially elevated serum TGF-
     1 concentrations of between 90  –  150 ng/ml, with a mean of 
120 ng/ml (  Fig. 6 C  ) (  26  ). Young tumor-free mice had 50   ±   
10 ng/ml TGF-     1 in the serum. Old B6 mice had slightly 
increased TGF-     1 levels compared with young LoxP-Tag 
mice. LoxP-Tag mice with PMLs (defi  ned by the presence of 
anti-Tag IgG antibodies in the serum) revealed TGF-     1 
concentrations almost as high as LTB mice (106   ±   25 ng/ml; 
  Fig. 6 C  ). In essence, tumor-induced tolerance and CTL un-
responsiveness against unrelated antigens is associated with 
tumor-specifi  c IgG antibodies, high serum levels of TGF-     1, 
and large numbers of iMCs in the spleen and tumor. The 
source of the elevated TGF-     1 is diffi   cult to identify because 
many cell types are able to express TGF-     1. Because we 
found a good correlation between serum Tag-specifi  c IgG 
antibodies and elevated TGF-     1 levels, and TGF-     1  –  IgG 
complexes have been implicated in CTL suppression (  23, 24  ), 
we evaluated TGF-     1  –  producing IgG  +   B cells. By immuno-
histology, a substantially increased number of IgG/TGF-     1 
double-positive cells were detected in perihilar lymph nodes 
of kidneys of tumor-bearing LoxP-Tag compared with young 
tumor-free LoxP-Tag mice (  Fig. 6 D  ; and Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20072016/DC1). 
However, we also found anti  –  TGF-     1 immune reactivity 
that did not overlap with anti-IgG reactivity. This result sug-
gested that IgG-producing B cells are at least one potential 
source for the elevated TGF-     1 levels in tumor-bearing 
LoxP-Tag mice. 
  Large nonimmunogenic tumors do not induce general 
CTL unresponsiveness 
  Finally, we asked whether nonimmunogenic tumors also in-
duce CTL unresponsiveness to unrelated antigens. LoxP-Tag 1694 IMMUNOGENIC CANCER CAUSES GENERAL CTL UNRESPONSIVENESS   | Willimsky et al. 
    Figure 6.         Tumors in LoxP-Tag mice induce an increase in iMCs and serum TGF-    1 levels.   (A and B) For analysis of iMCs, single-cell prepara-
tions of spleen and tumor were double stained with antibodies against Gr-1 and CD11b or Gr-1 and c-kit, respectively, to assess CD11b  + /Gr-1 +   (top) 
and c-kit  + /Gr-1 +   (bottom) cells in spleens of 2  –  3-mo-old LoxP-Tag mice (young Tg), 14  –  17-mo-old wild-type mice (old B6), 6  –  13-mo-old tumor-
bearing LoxP-Tag mice with PMLs, 7  –  19-mo-old LTB LoxP-Tag mice, and 3  –  4-mo-old LoxP-Tag   ×   Alb-Cre double-transgenic mice (TB Tg   ×   Alb-Cre) 
with large liver tumors. Numbers show the percentage of double-positive cells of nonlymphocytes. One representative example per experimental 
group is shown in A, and all data for splenic CD11b  + /Gr-1 +   and c-kit   + /Gr-1 +   cells  (   ) and tumor-infi  ltrating CD11b  + /Gr-1 +   cells  (   ) are shown in B 
(horizontal bars indicate mean values). (C) Serum obtained from individual young LoxP-Tag (Tg; 3 mo old;   n   = 5), old C57BL/6 mice (B6; 12  –  23 mo 
old;   n   = 5), LoxP-Tag transgenic mice with PMLs (PML Tg; 6  –  13 mo old;   n   = 4), LTB LoxP-Tag transgenic mice (LTB Tg; 7  –  19 mo old;   n   = 4), and LTB JEM VOL. 205, July 7, 2008 
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we assume abundant cell death of Tag-expressing cells 
(  40  ) and chronic tumor antigen release under CTL tolero-
genic conditions. 
  Split tolerance and no necessity of immune escape 
  The time point of fi  rst detection of anti-Tag IgG antibodies 
in the serum of LoxP-Tag mice marked the time point of 
tolerance. This sounds paradoxical. Tolerance was measured 
by the inability to kill Tag peptide IV  –  loaded spleen cells and 
the failure to reject Tag-positive tumor cells that were re-
jected in young LoxP-Tag mice. On the other hand, the anti-
Tag IgG antibodies, the generation of which likely involves 
functional CD4  +   T cell help, indicates a productive anti-Tag 
immune response. Therefore, it is debatable whether Tag in 
LoxP-Tag mice is immunogenic or antigenic. The split toler-
ance is remarkable because some investigators proposed that 
nascent tumors are unable to induce functional T cells (e.g., 
because of the lack of co-stimulation; reference   41  ), whereas 
others suggested that nascent tumors are able to do so (  42  ). 
Even though the Tag-specifi  c CD4  +   T cells have to be ana-
lyzed, our data support the former hypothesis with regards to 
CTLs and the latter hypothesis with regards to CD4  +   T cells, 
yet they are deviated to a phenotype that does not allow them 
to support CTL generation. What is often considered as tu-
mor immunity should in fact be regarded as innocent tumor 
reactivity. Thus, the net eff  ect of the split tolerance is tolerance 
of the cancer cells: it is unlikely that the humoral immune re-
sponse has tumoricidal activity, because Tag is a nuclear anti-
gen and not accessible to antibodies. 
  The long latency is probably caused by the multistage 
process of carcinogenesis and not CTL-mediated tumor con-
trol, because the mice had acquired Tag-specifi  c tolerance 
upon or close to the fi  rst recognition of the PMLs. As has 
been mentioned before, the anti-Tag IgG antibodies might 
involve CD4  +   T cell help; therefore, their occurrence might 
indicate the time point when CTLs become aware of Tag. 
Because we failed to detect a window of functional CTL ac-
tivation, our data suggest that sporadic cancer in our model 
is unable to induce functional CTLs. Instead, CTLs with an 
anergic phenotype expand in tumor-bearing LoxP-Tag mice 
(  26  ). This may explain why highly immunogenic tumors pro-
gressively grow. Our data argue strongly against immunoed-
iting or immune escape (  42  ), direct evidence of which is 
lacking ( 33, 43, 44 ). If spontaneous tumors, even if very immuno-
genic, are unable to induce a protective T cell response, then 
there is no need for tumor cells to escape T cell recognition 
or destruction. Potentially immune-suppressive mechanisms 
like increased levels of serum TGF-     1 or expansion of iMCs 
could be the consequence, not the cause, of the default im-
mune response. 
chemical carcinogenesis is strongly infl  uenced by nonspecifi  c 
infl  ammatory responses that may be altered in immune-
defi  cient mice. Unfortunately, altered chemical carcinogen-
esis in immune-defi  cient compared with immune-competent 
mice has been erroneously attributed to T cell  –  specifi  c anti-
tumor eff  ects (  33  ). Several sporadic cancer models have been 
developed, e.g., by oncogene activation in the adult mouse 
through Cre recombinase  –  mediated deletion of a stop cas-
sette (  34  ) or by spontaneous recombinations (hit and run) 
(  35  ). In these models, the antitumor immune response has 
not been analyzed. LoxP-Tag mice provide a unique spo-
radic cancer model because the oncogene is stochastically 
activated in individual cells without experimental manipula-
tion. Because young LoxP-Tag mice eff  ectively respond to 
Tag, the initiating oncogene (e.g., shown by the rejection of 
transplanted Tag-positive tumor cells in young mice), the 
immune response against the developing tumor can be ana-
lyzed throughout the long process leading to malignancy. 
Tumor initiation and progression may be variable from mouse 
to mouse because of the stochastic nature of the model. It 
showed, as based on the induction of anti-Tag antibodies 
and verifi  ed in several cases histologically, that LoxP-Tag 
mice contain PMLs at around 6  –  9 mo but obvious tumor 
burden occurred between 12 and   >  24 mo. In this regard, 
sporadic cancer in LoxP-Tag mice closely resembles cancer 
in humans that may persist in a premalignant state long be-
fore clinical appearance (  36, 37  ). However, a caveat of the 
model is that because of the stochastic nature of oncogene 
activation, we do not know in how many cells and at which 
level Tag is expressed in the lifetime of LoxP-Tag mice. One 
can assume, as verified in several mice, that several PMLs 
occur in the same mouse, but only few or often only one fi  -
nally progressed. Even though multiple cancers have been 
observed in humans (  38  ) (e.g., induced by chemical carcino-
gens, a phenomenon termed fi  eld cancerization; reference   39  ), 
these lesions unlikely share the same tumor-specifi  c antigens. 
In contrast, PMLs in LoxP-Tag mice share Tag as antigen. 
The early time point of Tag-specifi  c tolerance (     6  –  9 mo), 
when mice reveal PMLs, could therefore be caused by the 
multiplicity of Tag-positive lesions. Whether mice with a 
single cancerous lesion develop tolerance at a later time point 
remains to be analyzed. It should be noted that the number 
of PMLs in the kidney, a frequent site of tumor develop-
ment, at the time when Tag-specifi  c tolerance had already 
manifested was low. By complete sectioning of the kidneys 
of 6  –  7-mo-old Tag-tolerant LoxP-Tag mice, between two 
and fi  ve lesions were detected in four out of seven ana-
lyzed mice, all of which were microscopically small. Because 
the premalignant cells appeared to proliferate (i.e., were Ki-67  +  ) 
without apparent progression for an extended time period, 
LoxP-Tag   ×   Alb-Cre double-transgenic mice (LTB Tg   ×   Alb-Cre; 3  –  4 mo old;   n   = 4) was analyzed for TGF-     1 by ELISA. Error bars represent SD. (D) Perihilar 
lymph nodes of kidneys obtained from young tumor-free LoxP-Tag mice and mice with PMLs were double stained for TGF-     1 (red) and IgG (green); 
nuclei were counterstained with DAPI. Cells that are double positive for IgG antibodies and TGF-     1 are shown in orange (merge). Additional stainings 
for PML and LTB mice are shown in Fig. S3 (available at http://www.jem.org/cgi/content/full/jem.20072016/DC1). Bar, 20   μ  m.     
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unexpected, because the double-transgenic mice had the 
highest frequency of iMCs that was considered to be suffi   -
cient to inhibit CTL activation. Because LoxP-Tag   ×   Alb-Cre 
mice had developed tolerance for Tag early in life and Tag is 
the dominant transplantation rejection antigen, tumors in the 
double-transgenic mice are nonimmunogenic in comparison 
to tumors that grow in single transgenic LoxP-Tag mice. 
Immunogenicity, not tumor burden is, therefore, the pri-
mary cause for the general CTL unresponsiveness. Tumor bur-
den in double-transgenic LoxP-Tag occurred very fast because 
Tag was activated in the whole liver. We cannot exclude, 
therefore, that the longer latency with the continuously pre-
sent Tag expression in single-transgenic LoxP-Tag mice con-
tributed to the general CTL unresponsiveness. Collectively, 
we suggest that the degree of general CTL unresponsiveness 
directly refl  ects the degree of tumor immunogenicity. 
  At the current time, we can only speculate about the 
cellular and molecular mechanisms of how general CTL un-
responsiveness is mediated. Recently, iMCs were suggested 
to be renamed as myeloid-derived suppressor cells, a defi  ni-
tion that implies that they always act immune suppressive (  48  ). 
  General CTL unresponsiveness 
  Over time and subsequent to Tag-specifi  c tolerance, LoxP-
Tag mice developed a profound general CTL unresponsive-
ness. It was associated with increased serum levels of TGF-    1, 
expansion of iMCs, and the presence of anti-Tag IgG anti-
bodies. Because we have seen in the previous paragraph that 
escape from immune surveillance is likely not the reason 
for the immune suppression, the question arises why and by 
which mechanism is the general CTL unresponsiveness in-
duced? Our data suggest that the chronic and persistently 
immunogenic tumor antigen sustains the default CTL re-
sponse that cannot be turned down, resulting in general CTL 
unresponsiveness. Whether TGF-     1, which has consistently 
been shown to suppress CTL responses (  45  –  47  ), is the cause 
of the Tag-specifi  c tolerance or the symptom of the persistent 
tumor antigen remains unclear. However, because TGF-     1 
levels were already elevated in mice with PMLs and persisted 
at high levels for a very long time, it likely contributed to the 
general CTL unresponsiveness. This is supported by the nor-
mal anti-HY CTL responses and normal TGF-     1 levels in 
Tag-tolerant LoxP-Tag   ×   Alb-Cre mice. This was rather 
    Figure 7.         Large nonimmunogenic tumors in LoxP-Tag   ×   Alb-Cre double-transgenic mice do not induce general CTL unresponsiveness.  
(A) LoxP-Tag   ×   Alb-Cre double-transgenic mice are tolerant for Tag. LoxP-Tag   ×   Alb-Cre double-transgenic mice (1  –  2 mo old;   n   = 3) were immunized s.c. 
with 10  6   Tag +   16.113 cells and subjected to a Tag-specifi  c peptide IV in vivo kill assay 2 wk later. As a control, naive mice (2 mo old;   n   = 2) and immunized 
wild-type mice (2 mo old;   n   = 2) were used. The percentage of specifi  c killing of Tag-specifi  c peptide IV  –  loaded spleen cells is shown (horizontal bars indi-
cate mean values). (B) LoxP-Tag   ×   Alb-Cre double-transgenic mice (Tg   ×   Alb-Cre) develop large tumors in the liver at 3  –  4 mo of age. MRI analysis re-
vealed livers to be four to fi  ve times larger in size in comparison to livers from 3  –  4-mo-old LoxP-Tag mice (Tg). (C) Immunohistochemical analysis using 
Tag-specifi  c antibody shows strong Tag expression in liver tumors that consist of hepatocellular and cholangiocellular cell carcinoma (HCC and CCC, re-
spectively). Bar, 200   μ  m. (D) LoxP-Tag   ×   Alb-Cre mice with large liver tumors at 3  –  4 mo of age (  n   = 3) were immunized with 5   ×   10  6   male spleen cells and 
subjected to an HY-specifi  c in vivo kill assay 2 wk later, as described in   Fig. 1  . Naive and HY-immunized C57BL/6 (B6) mice served as controls. The percent-
age of specifi  c killing of male cells is shown (horizontal bars indicate mean values).     JEM VOL. 205, July 7, 2008 
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the best indication that human cancers are not dramatically 
diff  erent in terms of immunogenicity compared with those 
in LoxP-Tag mice comes from the observation that PMLs in 
LoxP-Tag mice and primary carcinomas in humans are both 
often infi  ltrated by T cells. In humans, these tumor-infi  ltrating 
lymphocytes (TILs) have been associated with a good prog-
nosis, which has been interpreted as a tumoricidal T cell re-
sponse (  57, 58  ). Our data support the observation but not 
the interpretation. Mice with PMLs and a strong T cell infi  l-
trate at the age of 6  –  7 mo had a comparably good prognosis, 
yet they had already acquired Tag-specifi  c tolerance. The TILs, 
therefore, probably refl  ect a cancer-promoting infl  ammatory 
response (  59, 60  ) induced by the PMLs, not a tumor-eradi-
cating T cell response. Whether the TILs in PMLs of LoxP-
Tag mice are innocent bystander cells of the infl  ammatory 
response or cancer-promoting remains to be determined. 
  In conclusion, sporadic cancers do not sneak through and 
do not induce concomitant immunity but are recognized at 
the premalignant stage and induce a default immune response. 
The data argue strongly against immunoediting (  42  ), direct 
evidence of which is lacking (  33, 43, 44  ). Provided that similar 
mechanisms that we observe in the mouse model also occur in 
cancer patients, our data have to be seen as a cautionary note 
for therapeutic cancer vaccines: the more immunogenic the 
target antigen, the higher the preexisting immune suppression. 
However, they also have to be seen as a positive note for 
adoptive T cell therapy: the best target antigens are retained 
on the cancer cells; methods to eliminate immune suppression 
before T cell transfer have been developed (  61, 62  ). 
  MATERIALS AND METHODS 
  Animals.     LoxP-Tag transgenic mice were described previously (  26  ). 
C57BL/6 mice were obtained from Charles River Laboratories, Alb-Cre 
transgenic mice (B6.Cg-Tg(Alb-cre)21Mgn/J) were purchased from the 
Jackson Laboratory, and Rag-2       /       mice (129S6(B6)-Rag2tm1Fwa) mice 
were obtained from Taconic. Mice were housed at the animal facilities of 
Charit  é   (Campus Benjamin Franklin) and Max-Delbr  ü  ck-Center for Mo-
lecular Medicine. All experiments were in accordance with institutional, 
state, and federal (Landesamt f  ü  r Arbeitsschutz, Gesundheitsschutz und tech-
nische Sicherheit, Berlin) guidelines. 
  Immunization/tumor transplantation.     Mice were immunized at the 
ages indicated in the fi  gures either by s.c. injection of 10  6   Tag  +   16.113 cells 
(Tag-specifi  c immunization; reference   26  ) or 10  7   MC57-gp33-Hi cells 
(LCMV-gp33 peptide  –  specifi  c immunization; reference   27  ), or i.p. injec-
tion of 5   ×   10  6   male spleen cells (HY-specifi  c immunization). In tumor 
challenge experiments, 10  6   Tag  +   16.113 or MC57-gp33-Hi cells were in-
jected s.c. Animals that rejected 16.113 cells were monitored for at least 60 d. 
In the tumor transplantation experiments, mice were scored tumor bearing 
when the tumor size was   ≥  10 mm in diameter. At this size, tumors had a mean 
volume of 425   ±   75 mm  3  , which is best approximated by use of the formula 
for hemi-ellipsoids: vol = lwh(1/2). 
  In vivo kill assays.     Tag-specifi  c peptide IV (VVYDFLKL; reference   5  ) and 
gp33-41 peptide  –  specifi  c (KAVYNFATM; reference   63  ) in vivo cytotoxic-
ity assays were performed as previously described (  26  ). For gp33 peptide, as-
says were performed 8  –  10 d after immunization. For analysis of CTL activity 
against the HY antigens, spleen cells from male and female C57BL/6 mice 
were labeled with CSFE in a fi  nal concentration of 0.75   μ  M (CFSE  high  ) or 
0.075   μ  M (CFSE  low  ), respectively, for 15 min at room temperature. Cells were 
The experimental systems to analyze their immune-suppres-
sive potential were restricted to an in vitro analysis in which 
the addition of iMCs inhibited the activation of CTLs against 
tumor and unrelated antigens (  15, 17, 49  ). Indeed, the iMCs 
appeared to consistently inhibit CTL responses in vitro (  18  ). 
However, the dramatic expansion of iMCs and tumor burden 
in LoxP-Tag   ×   Alb-Cre mice did not cause CTL unrespon-
siveness in vivo. Whether iMCs in our model suppress CTL 
responses in vitro is not known, but even if they do, the in 
vivo data may be more relevant. Therefore, we prefer to call 
them iMCs rather than myeloid-derived suppressor cells, be-
cause they obviously do not always suppress unrelated CTLs. 
  The question remains as to why CTL responses against 
unrelated antigens were suppressed in LoxP-Tag but not in 
LoxP-Tag   ×   Alb-Cre mice even though iMCs were ex-
panded to high frequencies in both mouse lines. One possibility 
is that the iMCs, known to be a heterogenous cell population, 
are phenotypically diff  erent in the two mouse lines. They could, 
for instance, diff  er in the production of immune-suppressive 
molecules such as nitric oxide or arginase (  17, 19, 50  ). How-
ever, an alternative possibility is one reminiscent of a mecha-
nism suggested by Rowley et al. (  22  –  24  ). They proposed that 
chronic exposure of a fi  rst antigen, in this case sheep red 
blood cells, induced B cells to secrete IgG-latent TGF-     1 
complexes. Through Fc receptors, this complex is taken up by 
myeloid-derived cells that activate the latent form of TGF-
     1, which then, in turn, is used to inhibit activation of CTLs 
against unrelated antigens (  22  –  24  ). Specifi  c antibodies, non-
dissociated IgG  –  TGF-     1 complexes, monocytes/macrophages, 
and Fc receptors were all necessary for inhibition of CTL 
priming in vitro. Several lines of evidence indicate that gen-
eral CTL unresponsiveness in LoxP-Tag mice is mediated by 
a similar mechanism: (a) iMCs alone were not suffi   cient to 
inhibit unrelated CTL responses, as observed in LoxP-Tag   ×   
Alb-Cre mice; (b) inhibition of unrelated CTL responses cor-
related with an increase in TGF-     1 and anti-Tag IgG anti-
bodies, as seen in LoxP-Tag but not LoxP-Tag   ×   Alb-Cre mice; 
(c), iMCs expressed Fc-receptors; and (d) IgG  –  TGF-     1 double-
positive cells were detected in Tag-tolerant LoxP-Tag mice. 
Future studies are needed to elucidate the precise mechanism 
of general CTL unresponsiveness in old LoxP-Tag mice. 
  Relevance of LoxP-Tag mice for human cancer 
  It is diffi   cult to judge how the immunogenicity of tumors in 
humans compares with that in our tumor model. On the one 
hand, human tumors are often assumed to be less immuno-
genic than mouse tumors. On the other hand, increased iMC 
frequencies (  32  ), elevated TGF-     1 serum levels (  51  ), tumor-
reactive antibodies (  52, 53  ), and strongly increased tumor-
reactive CTLs without apparent regression (  54  –  56  ) have all 
been detected in cancer patients but are not yet analyzed in 
the same patients. Additionally, memory CTL responses that 
might be the most frequent in (usually elderly) cancer pa-
tients are normal in tumor-bearing LoxP-Tag mice. Therefore, 
one would not expect frequent general CTL defi  ciency or 
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ters: TR, 308 ms; TE, 4.7 and 10 ms; fl  ip angle, 70  °  , NEX, 22; FOV, 150   ×   
75 mm; matrix, 256   ×   128; and slice thickness, 3 mm with a resolution of 
0.7   ×   0.6 mm for the CP Breast Array Coil and 1 mm with a resolution of 
0.2   ×   0.2 mm for the Loop Flex Coil (small surface). 
  Online supplemental material.     Fig. S1 shows additional representative 
PMLs in mice that recently developed anti-Tag antibodies but without 
macroscopically detectable tumors. Fig. S2 shows FoxP3 control staining of 
lymph nodes. Fig. S3 shows the analysis of IgG and TGF-     1  –  expressing 
cells in draining lymph nodes of mice with PMLs and tumors. Fig. S4 shows 
a phenotypic analysis of CD11b-positive cells obtained from young LoxP-
Tag mice, LoxP-Tag mice with PMLs, and tumor-bearing LoxP-Tag   ×   
Alb-Cre mice. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20072016/DC1. 
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